• by bcarlson@marketresearch.com
  • December 1 2015


Pfizer Back In Dermatologics with Allergan Deal

Pfizer Back In Dermatologics with Allergan Deal

Pfizer and Allergan’s announced merger at a total enterprise value of approximately $160 billion would bring Pfizer back into a therapeutic area of focus the company had previously eliminated, dermatology.  Several of Allergan’s flagship products are in the therapeutic areas of dermatology and aesthetics, including brands like Botox and the cosmetic treatment Juvéderm. The healthcare market researcher’s report, World Market for Prescription Dermatological Drugs, represents the ninth time that Kalorama has described the global prescription dermatological drugs market and identified the major factors that may help to shape the market for treatments in the future.  

The tax inversion scrutiny with respect to the proposed merger will get a attention, we think there are a number of market considerations behind this action.   The dermatology space is fast-growing and some of the top treatments are involved.  Some media accounts have noted opposition to this deal, the latest of what have become known as “tax inversion” deals. The merger would create the world’s largest drug company and move Pfizer-Allergan’s headquarters to Ireland, where the corporate tax rate is 18 percent. The U.S. corporate rate is 35 percent. 

Should the transaction be completed, Pfizer would regain access to some of the therapeutic areas of focus on which the company had previously cut back. In 2007, Pfizer had discontinued their participation in the dermatology, ophthalmology, and gastrorenterology (GI) areas. Allergan’s key therapeutic categories are dermatology and aesthetics, eye care, central nervous system (CNS) disorders, women’s health and urology, anti-infectives, and GI. In defending the deal, Pfizer states that with the merger the company’s businesses will be significantly enhanced by the addition of a growing revenue stream from Allergan’s brands.

The pharmaceutical industry is facing a tougher environment in general, due to harder regulations for gaining approvals for mainstream products, economic issues, and a dwindling pipeline of new products. Reliance on blockbuster drugs is all but over, causing a shift of focus for many drug research and development entities. By focusing on cosmetic medications, many manufacturers are realizing less scrutiny from the FDA and a growing need in the niche markets such as dermatology. This transition will play a role in the future development of the dermatological industry in the years ahead.

These are dynamic times for the prescription dermatological drug industry. The driving forces for the prescription dermatological drugs market include growth and aging of the worldwide population. The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. Industry consolidation, investments in new technologies, and discovery of genetic links to disease are among the industrywide trends.

World Market for Prescription Dermatological Drugs